Selected article for: "acute respiratory virus and Middle East respiratory syndrome"
Author: Dong, Yetian; Dai, Tong; Wei, Yujun; Zhang, Long; Zheng, Min; Zhou, Fangfang
Title: A systematic review of SARS-CoV-2 vaccine candidates
  • Cord-id: 395rsxzu
  • Document date: 2020_10_13
    • ID: 395rsxzu
    Snippet: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that is highly pathogenic and has caused the recent worldwide pandemic officially named coronavirus disease (COVID-19). Currently, considerable efforts have been put into developing effective and safe drugs and vaccines against SARS-CoV-2. Vaccines, such as inactivated vaccines, nucleic acid-based vaccines, and vector vaccines, have already entered clinical trials. In this review, we provide an overview of the expe
    Document: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that is highly pathogenic and has caused the recent worldwide pandemic officially named coronavirus disease (COVID-19). Currently, considerable efforts have been put into developing effective and safe drugs and vaccines against SARS-CoV-2. Vaccines, such as inactivated vaccines, nucleic acid-based vaccines, and vector vaccines, have already entered clinical trials. In this review, we provide an overview of the experimental and clinical data obtained from recent SARS-CoV-2 vaccines trials, and highlight certain potential safety issues that require consideration when developing vaccines. Furthermore, we summarize several strategies utilized in the development of vaccines against other infectious viruses, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), with the aim of aiding in the design of effective therapeutic approaches against SARS-CoV-2.

    Search related documents:
    Co phrase search for related documents
    • absence pneumonia and acute infection: 1, 2, 3, 4, 5, 6, 7, 8
    • accessory protein and acute infection: 1, 2, 3, 4, 5, 6
    • acid vaccine and adaptive immunity: 1, 2
    • acute ali lung injury and adaptive immune response: 1, 2
    • acute ali lung injury and adaptive immunity: 1
    • acute infection and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute infection and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute infection and adcc cell cytotoxicity: 1
    • acute infection and additional class: 1
    • acute infection and additional effort: 1